Organization
CytRx Corp. ▼
Topic
All Topics ▼
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
CytRx Corp.
CytRx, Class Dispute $685K Pump & Dump Deal Fee Award
April 19, 2018  •  Law360
... for their work on a proposed settlement in a derivative suit against CytRx Corp. directors in connection with a stock-pumping scheme, telling a Delaware state ...
CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR(TM) Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting
April 18, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR(TM) Drug Candidates at the AACR 2018 Conference
April 9, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Scoffs At $685K Fees Request In Shareholder Suit
March 26, 2018  •  Law360
... Law360 (March 26, 2018, 8:13 PM EDT) -- Biopharmaceutical company CytRx Corp. filed a brief late Friday in Delaware Chancery Court, opposing a ...
CytRx Reports 2017 Financial Results
March 19, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Corp. filed form 10-K
March 16, 2018  •  SEC
CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference
March 16, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Selects Four New LADR(TM) Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials
March 15, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018
March 12, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx to Present at the 30th Annual ROTH Conference
March 5, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Announces Expansion of Pharma Partnering Activities for Its LADR(TM) Ultra-High Potency Drug Candidates
February 28, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Announces the Presentation of New LADR(TM) Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
February 22, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
Global Kaposi Sarcoma Market 2017-2025: Size, Market Share, Application Analysis, Growth Trends, and Key Players - ResearchAndMarkets.com
February 12, 2018  •  Business Wire
... pipeline with excellent bioequivalence studies such as AT-0918 (Cytori Therapeutics, Inc.). Aldoxorubicin (CytRx Corporation) utilizes acid sensitive linker that selectively binds to albumin to allow ...
CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma
February 5, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Corporation to Present at Biotech Showcase 2018
January 3, 2018  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR(TM) Drug Candidates
December 6, 2017  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Corporation to Present at Upcoming Investor Conferences
November 27, 2017  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Investors Seek Cert. In Suit Over Cancer Drug Trial
November 20, 2017  •  Law360
... York (November 20, 2017, 3:08 PM EST) -- Investors suing biopharmaceutical company CytRx Corp. for allegedly misrepresenting the success of a late-stage trial of a ...
CytRx Corporation Regains Nasdaq Listing Compliance
November 17, 2017  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives
November 13, 2017  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Reports Third Quarter 2017 Financial Results
November 8, 2017  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
CytRx Corp. filed form 10-Q
November 8, 2017  •  SEC
Weekly Summary Corporate dividends, name changes, new listings
November 3, 2017  •  Associated Press
... g- Canadian funds OTHER CORPORATE NEWS AND LISTINGS: STOCK SPLITS THIS WEEK CytRx Corp 1 for 6 reverse split Marathon Patent Group Inc 1 for ...
CytRx Corporation Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline
November 2, 2017  •  PR Newswire
... CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today ...
Related News Feeds
Board and Executive Moves involving CytRx Corp.
Pharmaceuticals
Board and Executive Moves in Pharmaceuticals
Alumni of CytRx Corp.
Subscribe now for full coverage on CytRx Corp.
Start My Free Trial